Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075044 | 0.92 | ESR1 (0.50) | ESR1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL3468408 | 0.88 | ESR1 (0.56) | ESR1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL3468080 | 0.88 | ESR1 (0.51) | BCL2L1ESR1MEN1KMT2AMAPT | |
| SCHEMBL3468706 | 0.86 | KMO (0.47) | ESR1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL13161214 | 0.85 | DEGS1 (0.45) | ESR1DEGS1ALDH1A1 | |
| SCHEMBL27640751 | 0.84 | ESR1 (0.39) | MMP3BCL2L1ESR1MEN1KMT2A | |
| SCHEMBL3469077 | 0.84 | ESR1 (0.43) | ESR1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3467813 | 0.83 | ESR1 (0.44) | ESR1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL3468278 | 0.83 | FGFR1 (0.44) | MMP3ESR1MEN1KMT2AHSD17B1 | |
| Gsk-232802 SCHEMBL3467757 | 0.83 | ESR1 (0.55) | ESR1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | claimed |
| JP-2007500705-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | claimed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | claimed |
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7560589-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | ESR2, GPER1, ESRRG | MMP3 2206/4885BCL2L1 2375/4885ESR1 4/4885 |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | ESR2, GPER1, ESRRG | MMP3 2206/4885BCL2L1 2375/4885ESR1 4/4885 |
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | MMP3 2120/4885BCL2L1 2524/4885ESR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.